

Department of Medicine

Medical Grand Rounds

Michael E. Williams, M.D.
Byrd S. Leavell Professor of Medicine and
Professor of Pathology
Chief Hematology/Oncology Division
University of Virginia Health System
Charlottesville, VA

**“Targeted Therapeutics for Lymphoma and CLL:
The end of chemotherapy?”**

Wednesday, January 13, 2015

12:00 – 1:00pm

Old Jordan Auditorium 1-5

Disclosures:

Dr. Williams has a financial relationship with Takeda and Celgene researching Lymphoma.

CME Learning Objectives

- 1) Understand the use of novel targeted therapeutics for Mantle Cell Lymphoma and CLL.
- 2) Recognize changing cancer treatment algorithms in the era of personalized medicine.

The University of Virginia School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Virginia School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Virginia School of Medicine awards 1.0 hours of participation (equivalent to AMA PRA Category 1 Credits™) to each non-physician participant who successfully completes this educational activity. The University of Virginia School of Medicine maintains a record of participation for six (6) years.